Abstract : Endothelin-1 is a peptide with many functions including bronchoconstriction and the stimulation of fibroblasts, and myofibroblasts, and airway smooth muscle cell proliferation. These functions are related to airway remodeling and endothelin-1 is known to be upregulated in the epithelium of patients with severe asthma. We thus sought to elucidate the mechanisms underlying endothelin-1 expression in bronchial epithelial cells in vitro. The human bronchial epithelial cell line BEAS-2B was grown in culture and then treated with tumor necrosis factoralpha TNF-, interleukin-4 IL-4 , interleukin-13 IL-13 , and transforming growth factor-beta TGF-. Expression of endothelin-1 mRNA and protein was quantified by real-time polymerase chain reaction and enzyme-linked immunosorbent assay, respectively. We also repressed expression of the key transcription factor in the pathogenesis of severe asthma, nuclear factor-kappa B NF-B , using small interfering RNA siRNA . TNF-and TGF-signi cantly increased the release of endothelin-1 protein into the culture medium of BEAS-2B cells at 24 h after treatment compared to untreated cells ; however, the Th2 cytokines, IL-4 and IL-13, had no effect. Endothelin-1 mRNA expression was also upregulated by TNFand TGFwith a peak time point at 4 h after stimulation. Finally, the combination of TNF-and TGF-synergistically increased both endothelin-1 protein secretion and mRNA expression, and this upregulation was signi cantly suppressed in cells transfected with siRNA to repress NF-B expression. TNF-and TGF-synergistically upregulate the expression of endothelin-1 in human bronchial epithelial cells, possibly via the activity of NF-B. Our ndings thus suggest NFBa as a potential therapeutic target for the regulation of airway remodeling.
Introduction
The pathophysiology of asthma is characterized by chronic airway in ammation and remodeling such as subepithelial fibrosis, deposition of extracellular matrix protein, hypertrophy and hyperplasia of airway smooth muscle, and goblet cell hyperplasia. Increased bronchial wall thickness caused by such airway remodeling contributes to air ow obstruction and the subsequent treatment resistance in severe asthma 1 .
Endothelin-1 is a 21-amino acid peptide with vasoconstrictive and bronchoconstrictive activities 2 . It also functions to stimulate the proliferation of broblasts, myo broblasts, and airway smooth muscle cells, as well as the deposition of extracellular matrix and the differentiation of broblasts into myo broblasts 3, 4 . These functions of endothelin 1 might therefore play a role in the pathogenesis of airway remodeling. Indeed, recent studies indicate that the expression of endothelin-1 is increased in severe asthma and contributes to airway remodeling therein 5, 6 , while data from murine models of asthma corroborated that endothelin-1 contributes to airway remodeling 7 . All of these studies identi ed bronchial epithelial cells as an important source for endothelin-1 production, supported by in vitro experiments showing that cultured bronchial epithelial cells also produce endothelin-1 8 . In the present study, we used this in vitro system to further investigate the mechanisms underlying endothelin-1 production in human bronchial epithelial cells.
Methods

Cell culture and reagents
The human bronchial epithelial cell line BEAS-2B was purchased from the American Type Culture Collection Manassas, VA, USA . This cell line was derived from non-tumor bronchial epithelial cells transformed with the SV40 virus 9 . The cells were cultured in Dulbecco s modied Eagle s medium DMEM /Ham s F12 F12 medium supplemented with 10 fetal bovine serum FBS , 100 U/ml penicillin, and 100 ng/ml streptomycin Invitrogen, Tokyo, Japan and maintained at 37 C in a humidified 5 CO 2 atmosphere. We purchased recombinant human cytokines, tumor necrosis factor-alpha TNF-, transforming growth factor-beta1 TGF-1 , interleukin-4 IL-4 , and interleukin-13 IL-13 , from R&D Systems Tokyo, Japan . Cells were treated with each cytokine as described below and then the supernatants and RNA from the cells were collected and stored at 80 C.
Enzyme-linked immunosorbent assay ELISA assay for endothelin-1 protein production
The concentrations of secreted endothelin-1 in the cell culture supernatants were measured using enzyme-linked immunosorbent assay ELISA kits R&D Systems . Standards and samples were added to 96-well microtiter plates coated with the anti-endothelin-1 antibody. After incubation at room temperature for 2 h, the wells were washed 5 times with washing buffer. A horseradish peroxidase-conjugated secondary antibody against endothelin-1 was then added to the wells and incubated at room temperature for 2 h. The wells were washed 5 times with washing buffer, before adding a substrate solution stabilized hydrogen peroxide and tetra-methylbenzidine and incubating the plate at room temperature for 30 minutes to visualize the antibody binding. Sulfuric acid was added to arrest the reaction, and the absorbance at 450 nm was measured using an ELISA plate reader Glomax-Multi Detection System, Promega, Tokyo, Japan .
RNA purification and cDNA synthesis
Total RNA was extracted from cells after incubation with and without the indicated reagents using ISOGEN Nippon-Gene, Tokyo, Japan . cDNAs were synthesized from isolated RNA templates using a High-Capacity cDNA Archive Kit Applied Biosystems, Tokyo, Japan .
Real-time polymerase chain reaction PCR
A pre-designed TaqMan probe for endothelin-1 was purchased from Applied Biosystems, and then labeled with a uorescent reporter dye FAM at the 5 end and a downstream quencher dye TAMRA at the 3 end. The TaqMan Ribosomal RNA probe, labeled with a uorescent reporter dye VIC , was used as an internal control. Each reaction consisted of 2X Universal Master Mix Applied Biosystems , primers, labeled probes, and 100 ng cDNA in a total volume of 50 l. Ampli cation conditions consisted of an initial incubation at 95 C for 10 min followed by 40 cycles of 95 C for 15 s and 60 C for 1 min. Ampli cation and uorescence measurements were carried out during the elongation step using a Real-Time PCR system 7,500 Applied Biosystems . Data are shown as fold induction of mRNA compared with non-stimulated control cells.
Repression of NF-B expression with siRNA
To analyze the transcriptional mechanisms of endothelin-1 expression in bronchial epithelial cells, we focused our study on the role of nuclear factor-kappa B NF-B which is a key transcription factor in the pathogenesis of severe asthma. We utilized small interfering RNA siRNA -mediated repression of NF-B expression, as previously reported 10 . BEAS-2B cells were seeded into 6-well plates and allowed to grow to 50 con uence, before being transfected with 50 nm siRNA for NF-B p65 subunit ; RELA or scrambled RNA negative control Applied Biosystems plus 5 l Lipofectamine 2,000 Promega and grown in DMEM/F12 with 10 FBS without antibiotics for 24 h. Then, the cell media were changed to DMEM/F12 with 10 FBS, 100 U/ml penicillin, and 100 ng/ml streptomycin. After another 24 h, the cells were incubated with or without the indicated cytokines for 4 h for PCR or for 24 h for ELISA . Then cells were harvested and the supernatant was collected and stored at 80 C.
Statistical analysis
Data were expressed as the means standard error of the mean SEM . Statistical differences were determined by analysis of variance with a Fisher protected least signi cant differences test. Data were analyzed with Stat-View 5.0 Abacus Concepts, Inc., Berkeley, CA, USA .
Results
Increase of endothelin-1 protein production by TNF-and TGF-
The cytokines used in this study were chosen because of their reported pathogenic association with airway remodeling in asthma 1 . We first examined the effect of each cytokine on the secretion of endothelin-1 into the culture medium of BEAS-2B cells. TNFand TGFeach increased endothelin-1 secretion at 24 h after treatment P 0.05 compared with nontreated control cells Fig. 1 . In contrast, the Th2 cytokines IL-4 and IL-13 did not increase the secretion of endothelin-1. We therefore focused our study on the regulation of endothelin-1 expression by TNF-and TGF-and the underlying mechanisms thereof.
Time-dependent expression of endothelin-1 protein and mRNA after stimulation with TNF-
As an initial experiment, we observed the time course of endothelin-1 protein release into the cell culture medium and that of its cellular mRNA expression in response to TNF-treatment. The peak secretion of endothelin-1 occurred at 24 h after stimulation with 10 ng/ml TNF-P 0.05 compared with non-treated control cells Fig. 2A . On the other hand, the peak expression of endothelin-1 mRNA was observed at 4 h after the same stimulation, preceding protein production P 0.05 compared with non-treated control cells Fig. 2B .
Time-dependent expression of endothelin-1 protein and mRNA after stimulation with TGF-
We also analyzed the time course of endothelin-1 protein secretion and mRNA expression after stimulation with TGF-10 ng/ml . Peak secretion of endothelin-1 protein into the medium of BEAS-2B cells was observed at 24 to 72 h after stimulation with TGF-P 0.05 compared with non-treated control cells Fig. 3A . However, for TNF-, the peak expression of endothelin-1 mRNA was detected at 4 h after TGF-stimulation P 0.05 compared with non-treated control cells Fig. 3B . Therefore, we focused subsequent analyses of endothelin-1 secretion and mRNA production at 24 h and 4 h, respectively, after stimulation with TNFand/or TGF-.
Secretion of endothelin-1 protein and mRNA expression after stimulation with different doses of TNF-
Endothelin-1 protein secretion appeared to increase dose-dependently at 24 h after TNFstimulation of the BEAS-2B cells P 0.05 compared with non-treated control cells , with maximum expression observed with 10-100 ng/ml TNF- Fig. 4A . Similarly, the mRNA expression of endothelin-1 at 4 h after stimulation was also upregulated by TNFin a dose-dependent manner P 0.05 compared with non-treated control cells Fig. 4B . Therefore, we chose the dose of 10 ng/ml TNF-for subsequent endothelin-1 analyses.
Secretion of endothelin-1 protein and mRNA expression after stimulation with different doses of TGF-
Endothelin-1 secretion from the BEAS-2B cells also seemed to increase does-dependently at 24 h after TGFstimulation P 0.05 compared with non-treated control cells Fig. 5A . The difference in secretion was statistically signi cant between treated and control cells at 1-10 ng/ml TGF-, while the expression of endothelin-1 mRNA was upregulated by 10 ng/ml TGFat 4 h after stimulation P 0.05 compared with non-treated control cells Fig. 5B . Accordingly and as for TNF-, we chose the dose of 10 ng/ml TGFfor subsequent analyses of endothelin-1. 
Synergistic upregulation of endothelin-1 expression by TNF-and TGF-
We next observed the effects of stimulation with a combined treatment of TNF-and TGF-. Combination treatment significantly increased the total level of endothelin-1 protein in the medium of BEAS-2B cells at 24 h after treatment P 0.05 compared with stimulation by TNFor TGFalone Fig. 6A . This synergistic stimulation of endothelin-1 was also observed in the mRNA expression levels P 0.05 compared with stimulation by TNFor TGF-alone Fig. 6B .
Induction of endothelin-1 expression by TNF-is dependent upon the transcription factor NF-B
Finally, we explored the role of transcription factor NF-B in the mechanisms of endothelin-1 regulation in bronchial epithelial cells. First, real-time PCR was used to con rm that the NF- 
Discussion
In this study we demonstrated that pro-inflammatory cytokine, TNF-, and growth factor, TGF-, could synergistically stimulate the mRNA expression and protein secretion of 10 ng/ml each . Culture media were collected at 24 h after stimulation and then subjected to ELISA. Cells were harvested at 4 h after stimulation and subjected to real-time PCR. The data are presented as the means SEM of three independent experiments P 0.05 compared with nontreated control cells cont , P 0.05 compared to the cells stimulated with TNFor TGF-alone .
endothelin-1 protein from bronchial epithelial cells as measured by real-time PCR and ELISA, respectively. In contrast, Th2 cytokines did not change endothelin-1 expression or secretion. We further showed that these mechanisms partially depended on the transcription factor, NF-B, by siRNA-mediated NF-B knockdown experiments.
The cytokines IL-4 and IL-13 are reportedly important in the pathogenesis of asthma, and are known to cause airway remodeling and severe asthma. However, asthma is a disease encompassing multiple different phenotypes 11, 12 , and cytokines, such as TNF-and TGF-, might also play an important role in certain phenotypes of severe asthma. TNF-is a pleiotropic cytokine that upregulates the expression of adhesion molecules, cytokines, and chemokines in the bronchial mucosa of patients with asthma, implicating an important role for TNF-in the pathogenesis of severe asthma 13, 14 . Recent data also showed that TNFinhibits eosinophil apoptosis 15 , and that the TNF-pathway could be associated with airway hyper-responsiveness in obesity, one of the risk factors for the severity of asthma 16 . The exact mechanistic relationship between airway remodeling and TNF-has not been clari ed ; however, it is possible that endothelin-1, induced In turn, TGFis a multifunctional cytokine that exerts many biological effects including immunosuppressive and in ammation-regulatory effects. On the other hand, TGF-also seems to be pivotal in the pathogenesis of airway remodeling and severe asthma 17 , inducing brocyte differentiation and stimulating both fibroblast proliferation and the synthesis of extracellular matrix proteins 18 . TGFcan also initiate the epithelial-mesenchymal transition, a mechanism characterized by the acquisition of a mesenchymal phenotype in bronchial epithelial cells and observed in the epithelial cells of patients with severe asthma 19 . TGFis also expressed in eosinophils, one of the key in ammatory cells in asthma, and its expression therein is upregulated in severe asthma 20, 21 . Recent reports also indicated that TGF-expression correlates with the thickening of the basement membrane in children with asthma, even though these patients were using inhaled corticosteroids 22 . In concordance with this and as we demonstrated in this study, TGF-might contribute to the pathogenesis of airway remodeling through the upregulation of endothelin-1 expression in the bronchial epithelium.
In this study, TNF-and TGF-synergistically upregulated both the expression of endothelin-1 in human bronchial epithelial cells and the subsequent protein secretion from these cells, supporting an important role for both cytokines in the pathogenesis of airway remodeling and severe asthma. These effects seemed to depend on transcription, because TNFand TGFstimulation also upregulated endothelin-1 mRNA expression in a synergistic manner. To examine the potential transcriptional regulation further, we also tested the role of NF-B in endothelin-1 expression and secretion. NF-B is a key transcription factor for initiating inflammation in asthma. Many kinds of cytokines, chemokines, adhesion molecules, and growth factors can be activated by NF-B ; indeed, our studies demonstrated that NF-B activates inflammatory chemokines such as CCL-11, CCL-5, CXCL-8, and CXCL-10 in bronchial epithelial cells 10, 23, 24 .
Several reports also indicated that NF-B is activated in the epithelium of patients with asthma and is related to disease severity 25, 26 . NF-B is also an important regulator of growth factor expression and cell viability. In addition, the contribution of NF-B to airway remodeling has been reported in a murine asthma model 27 . These data are concordant with those obtained herein, and together implicate NF-B as a pivotal player in the regulation of endothelin-1 in bronchial epithelial cells. Such accumulating data supports the potential for endothelin-1 as a possible therapeutic target of asthma. Several antagonists, including bosentan, a dual antagonist of the endothelin receptors ETA and ETB, have been shown to repress airway in ammation, hyper-reactivity, and remodeling in a murine asthma model 28, 29 . However, to our knowledge, only a few clinical studies have targeted endothelin-1 in patients with asthma. In a pilot study to determine the effect of bosentan administration over four weeks in seven patients with poorly controlled asthma, Coyle and Metersky 30 were unable to demonstrate improvement in either lung function or asthma symptoms. Thus, a longer course of therapy and larger numbers of subjects might be necessary for a meaningful evaluation of the ef cacy of endothelin-1 antagonists in asthma.
Taken together, our results demonstrated that TNFand TGFsynergistically upregulate endothelin-1 in bronchial epithelial cells, and that the transcription factor NF-B might play an important role in this mechanism. These ndings suggest that NF-B might represent a therapeutic target against not only in ammation, but also airway remodeling.
